CELUW
Celularity IncKey Statistics
About Celularity Inc
Celularity Inc (CELUW) is a leading clinical-stage biotechnology company focused on advancing groundbreaking cell therapies that leverage the regenerative potential of human placental cells. By addressing critical health issues including cancer, autoimmune disorders, and degenerative diseases, Celularity aims to develop accessible off-the-shelf therapies that broaden treatment options for patients. Backed by a robust pipeline and a strong portfolio of intellectual property, the company is strategically positioned in the dynamic cell-based medicine landscape, poised to meet significant unmet medical needs and deliver transformative therapeutic solutions.
Fundamentals
| Revenue (TTM) | $26.55M |
| Gross Profit (TTM) | $6.48M |
| EBITDA | $-54.01M |
| Operating Margin | -492.10% |
| Return on Equity | -6367.00% |
| Return on Assets | -30.90% |
| Revenue/Share (TTM) | $1.04 |
| Book Value | $-1.32 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -61.30% |
| Quarterly Revenue Growth (YoY) | -77.40% |
| Shares Outstanding | 0 |
| Float | $18.87M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CELUW and any ticker you trade — then tracks every position and per-strategy win rate.